ClinicalTrials.gg
CompletedNCT04390334Updated Sep 16, 2020

A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.

A Phase 1 interventional study of Daridorexant and Famotidine in Healthy, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-16.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

A study in healthy male subjects to investigate the effect of famotidine and efavirenz on the way the body takes up, distributes, and gets rid of daridorexant.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in a language understandable to the subject prior to any study-mandated procedure.
  • Healthy male subjects aged between 18 and 45 years (inclusive) at Screening.

Exclusion criteria

Exclusion Criteria:

  • findings on the physical examination at Screening.
  • Clinically relevant abnormalities on 12-lead , measured after at least 5 min in a supine position at Screening.
  • Clinically relevant findings in clinical laboratory tests (hematology, clinical chemistry) at Screening and on Day -1.
  • History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment(s) (appendectomy and herniotomy allowed, cholecystectomy not allowed).
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • Moderate or severe renal insufficiency ( \< 60 mL/min calculated with the Cockcroft Gault formula) at Screening.
  • Total > 1.5 x at Screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment A: Daridorexant

    Single dose of 50 mg daridorexant

    Drug: Daridorexant

  • Experimental
    Treatment B: Famotidine & daridorexant

    Single dose of 40 mg famotidine followed 3 h later by a single dose of 50 mg daridorexant

    Drug: Daridorexant · Drug: Famotidine

  • Experimental
    Treatment C: Efavirenz

    600 mg efavirenz once daily in the evening from Day 5 to Day 14

    Drug: Efavirenz

  • Experimental
    Treatment D: Daridorexant & efavirenz

    Single dose of 50 mg daridorexant in the morning of Day 15 followed by a single dose of 600 mg efavirenz in the evening of Days 15 and 16

    Drug: Daridorexant · Drug: Efavirenz

Interventions

  • Daridorexant will be administered orally as 1 film-coated tablet of 50 mg strength to be taken in the morning under fasted conditions.

  • Famotidine will be administered orally as 1 film-coated tablet of 40 mg strength to be taken in the morning under fasted conditions.

  • Efavirenz will be administered orally as 1 film-coated tablet of 600 mg strength o.d. in the evening.

06

What researchers measure

Primary outcomes

  1. PK parameter of daridorexant: Maximum plasma concentration (Cmax)

    Time frame: Various time points during Treatment A through D (Total duration: up to 3 weeks).

  2. PK parameter of daridorexant: Time to reach Cmax (tmax)

    Time frame: Various time points during Treatment A through D (Total duration: up to 3 weeks).

  3. PK parameter of daridorexant: AUC from zero to infinity (AUC0-inf)

    Time frame: Various time points during Treatment A through D (Total duration: up to 3 weeks).

  4. PK parameter of daridorexant: AUC from zero to 48 hours (AUC0-48)

    Time frame: Various time points during Treatment A through D (Total duration: up to 3 weeks).

  5. PK parameter of daridorexant: Terminal elimination half-life (t½)

    Time frame: Various time points during Treatment A through D (Total duration: up to 3 weeks).

Secondary outcomes

  1. Treatment-emergent (S)AEs

    Time frame: Up to EOP for each of the Periods 1 to 3 and up to EOS for Period 4 (Total duration: up to 3 months)

07

Study locations

1 site
  • CRS Clinical Research Services Mannheim GmbH
    Mannheim, 68167, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Jun 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2020
First posted
May 15, 2020
StartActual
May 13, 2020
Primary completionActual
Jun 26, 2020
CompletionActual
Jun 26, 2020
Last update
Sep 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04390334
Responsible party
Sponsor
First posted
May 15, 2020
Start date
May 13, 2020
Primary completion
Jun 26, 2020
Completion
Jun 26, 2020
Last update
Sep 16, 2020

Study contacts

Clinical Trials Study Director
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Daridorexant · Efavirenz

Start the discussion